Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.48 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 3/20 | 0.42 |
| ▸ | ELANE | P08246 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324752 | 0.95 | CNR1 (0.51) | CNR1CNR2PKMHTR3AELANE | |
| SCHEMBL15897842 | 0.90 | PKM (0.55) | CNR1CNR2PKMELANE | |
| SCHEMBL15898196 | 0.87 | ELANE (0.57) | CNR1CNR2ELANEF2PLAU | |
| SCHEMBL17324732 | 0.86 | REN (0.44) | CNR1CNR2HTR3AELANEKDM4E | |
| SCHEMBL15897843 | 0.85 | PKM (0.52) | CNR1CNR2PKMHTR3AELANE | |
| SCHEMBL17324818 | 0.83 | KDM4C (0.50) | CNR1CNR2HTR3AELANEKDM4E | |
| SCHEMBL17324745 | 0.82 | KDM4E (0.52) | CNR1CNR2PKMHTR3AELANE | |
| SCHEMBL15897943 | 0.82 | ELANE (0.57) | CNR1CNR2ELANEF2PLAU | |
| SCHEMBL17324730 | 0.81 | CNR1 (0.48) | CNR1CNR2HTR3AKDM4EPARP1 | |
| SCHEMBL19997262 | 0.81 | CNR1 (0.47) | CNR1CNR2HTR3AKDM4EPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | CNR1 3961/4885CNR2 3572/4885PKM 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.